Figure 6.

Determination of risk. Comparison of patients identified by RNA-sequencing scores, proliferation, R-ISS, and cytogenetic risk factors in 535 consecutive previously untreated myeloma patients. Percentage of patients identified as high risk and presence of t(4;14), del17p, 1q21 (>3 copies) or t(14;16) is depicted at the top of the figure and plotted in dark red color. Light red color delineates medium risk or presence of three copies of 1q21, green color low risk and/or absence of the respective aberrations. Grey color depicts missing values. Percentage of patients identified as high risk calculated excluding missing values.